+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cell & Gene Therapy Clinical Trials Market - Global Forecast 2026-2032- Product Image
Cell & Gene Therapy Clinical Trials Market - Global Forecast 2026-2032- Product Image
New

Cell & Gene Therapy Clinical Trials Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 191 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5666050
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The cell and gene therapy clinical trials market is undergoing a transformative period, shaped by evolving scientific platforms, increasing regulatory rigor, and more complex supply chain requirements. Senior executives must navigate this dynamic environment to realize clinical and commercial goals in advanced therapy development.

Market Snapshot

The Cell & Gene Therapy Clinical Trials Market grew from USD 12.08 billion in 2025 to USD 13.94 billion in 2026. It is projected to expand at a CAGR of 15.61%, reaching USD 33.38 billion by 2032. This robust growth is fueled by advances in vector and cell engineering, a diverse ecosystem of specialized manufacturing partners, and expanding global regulatory engagement.

Scope & Segmentation

This report provides a comprehensive analysis of the clinical development, operational, and commercial landscape for cell and gene therapy programs worldwide. It maps the interplay between therapy modalities, platform technologies, supply chain integration, and regional dynamics.

  • Therapy Types: Cell therapy (including CAR T, dendritic, natural killer, and stem cells), gene therapy (viral and non-viral vectors), and tissue engineered products.
  • Vector Platforms: Viral vector constructs (adeno-associated, retroviral, adenoviral) and non-viral options (lipid nanoparticles, electroporation, naked DNA/RNA).
  • Cell Type Specialization: T cells (CAR T, TCR strategies), NK cells, dendritic cells, hematopoietic and mesenchymal stem cells.
  • Indication Focus: Oncology (solid tumors and hematologic malignancies), neurology (Alzheimer’s, Parkinson’s), and rare diseases (including cystic fibrosis, hemophilia).
  • Clinical Trial Phases: Early proof-of-concept through multi-region pivotal studies, with attention to regulatory interaction, data requirements, and endpoint selection.
  • Regional Coverage: Americas, Europe, Middle East & Africa, Asia-Pacific, each with unique regulatory, manufacturing, and clinical logistics environments.

Key Takeaways

  • Scientific innovation has moved from isolated demonstrations to scalable platforms, requiring early, cross-functional alignment among R&D, operations, and regulatory teams.
  • Manufacturing strategies are shifting from fragmented supply models toward integrated networks, combining contract and in-house capabilities to mitigate risk and improve consistency.
  • Evolving regulatory expectations now demand standardized potency assays, transparent safety monitoring, and greater data integration across clinical sites.
  • Therapy and vector selection decisions made early in development have lasting implications for regulatory engagement, commercialization, and long-term patient follow-up.
  • Organizations that integrate stakeholder-centric trial design and real-time operational oversight position themselves to accelerate patient access while safeguarding compliance.

Tariff Impact

Recent tariff measures in the United States have increased scrutiny on global clinical trial supply chains. These policies drive cost and procurement complexities for key inputs such as vector production components, specialty reagents, and cryogenic logistics equipment. Sponsors are responding by implementing diversified sourcing, maintaining strategic reserves, and considering local or regional manufacturing footprints to reduce lead times and lower disruption risk. The resulting market dynamics emphasize both operational adaptation and proactive supply chain risk management.

Methodology & Data Sources

This report synthesizes primary interviews with clinical leaders, regulatory experts, and manufacturing technologists, combined with analysis of technical literature, public trial registries, and current regulatory guidance. Data were validated through cross-referencing expert perspectives with trial protocols and iterative review cycles, ensuring comprehensive coverage of the cell and gene therapy clinical trials market.

Why This Report Matters

  • Enables senior decision-makers to benchmark operational resilience, supply chain strategy, and regulatory preparedness.
  • Provides actionable insights for aligning scientific choice, vendor selection, and trial design to support long-term portfolio growth.
  • Supports scenario planning in the face of regional policy changes and technology evolution, reducing risk across development stages.

Conclusion

Securing success in cell and gene therapy clinical trials requires matching scientific advances with operational rigor and strategic supplier diversification. Integrated, cross-functional approaches will help organizations navigate complexity and deliver consistent clinical outcomes in a rapidly evolving landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Cell & Gene Therapy Clinical Trials Market, by Therapy Type
8.1. Cell Therapy
8.1.1. CAR T Cell
8.1.2. Dendritic Cell Therapy
8.1.3. NK Cell Therapy
8.1.4. Stem Cell Therapy
8.2. Gene Therapy
8.2.1. Non-Viral Vector
8.2.1.1. Electroporation
8.2.1.2. Lipid Nanoparticle
8.2.1.3. Naked DNA/RNA
8.2.2. Viral Vector
8.2.2.1. Adeno-Associated Virus
8.2.2.2. Adenoviral
8.2.2.3. Retroviral
8.3. Tissue Engineered Products
9. Cell & Gene Therapy Clinical Trials Market, by Vector Type
9.1. Non-Viral Vector
9.1.1. Electroporation
9.1.2. Lipid Nanoparticle
9.1.3. Naked DNA/RNA
9.2. Viral Vector
9.2.1. Adeno-Associated Virus
9.2.2. Adenoviral
9.2.3. Retroviral
10. Cell & Gene Therapy Clinical Trials Market, by Cell Type
10.1. Dendritic Cell
10.2. NK Cell
10.3. Stem Cell
10.3.1. Hematopoietic Stem Cell
10.3.2. Mesenchymal Stem Cell
10.4. T Cell
10.4.1. CAR T
10.4.2. TCR
11. Cell & Gene Therapy Clinical Trials Market, by Indication
11.1. Neurology
11.1.1. Alzheimer Disease
11.1.2. Parkinson Disease
11.2. Oncology
11.2.1. Hematologic Cancer
11.2.1.1. Leukemia
11.2.1.2. Lymphoma
11.2.2. Solid Tumor
11.2.2.1. Breast Cancer
11.2.2.2. Melanoma
11.3. Rare Disease
11.3.1. Genetic Disorder
11.3.1.1. Cystic Fibrosis
11.3.1.2. Hemophilia
11.3.2. Metabolic Disorder
12. Cell & Gene Therapy Clinical Trials Market, by Trial Phase
12.1. Phase I
12.2. Phase II
12.3. Phase III
13. Cell & Gene Therapy Clinical Trials Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Cell & Gene Therapy Clinical Trials Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Cell & Gene Therapy Clinical Trials Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Cell & Gene Therapy Clinical Trials Market
17. China Cell & Gene Therapy Clinical Trials Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Adaptimmune Therapeutics plc
18.6. Allogene Therapeutics, Inc.
18.7. Astellas Gene Therapies, Inc.
18.8. Beam Therapeutics, Inc.
18.9. bluebird bio, Inc.
18.10. CRISPR Therapeutics AG
18.11. Editas Medicine, Inc.
18.12. Fate Therapeutics, Inc.
18.13. Gilead Sciences, Inc.
18.14. Iovance Biotherapeutics, Inc.
18.15. MeiraGTx Holdings plc
18.16. Novartis AG
18.17. Orchard Therapeutics Ltd
18.18. Passage Bio, Inc.
18.19. Rocket Pharmaceuticals, Inc.
18.20. Sangamo Therapeutics, Inc.
18.21. Spark Therapeutics, Inc.
18.22. uniQure N.V.
18.23. Vir Biotechnology, Inc.
List of Figures
FIGURE 1. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T CELL, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T CELL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T CELL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TCR, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TCR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TCR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ALZHEIMER DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ALZHEIMER DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ALZHEIMER DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PARKINSON DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PARKINSON DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PARKINSON DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RARE DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RARE DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RARE DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENETIC DISORDER, BY REGION, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENETIC DISORDER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 147. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENETIC DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 148. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENETIC DISORDER, 2018-2032 (USD MILLION)
TABLE 149. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 150. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 151. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 152. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 153. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMOPHILIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 154. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMOPHILIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 155. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY METABOLIC DISORDER, BY REGION, 2018-2032 (USD MILLION)
TABLE 156. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY METABOLIC DISORDER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 157. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY METABOLIC DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 158. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 159. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
TABLE 160. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
TABLE 161. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 162. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
TABLE 163. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
TABLE 164. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 165. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
TABLE 166. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
TABLE 167. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 168. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 169. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 170. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 171. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 172. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 173. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 174. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 175. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 176. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 177. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 178. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
TABLE 179. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, 2018-2032 (USD MILLION)
TABLE 180. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, 2018-2032 (USD MILLION)
TABLE 181. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 182. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
TABLE 183. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 184. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, 2018-2032 (USD MILLION)
TABLE 185. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
TABLE 186. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
TABLE 187. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENETIC DISORDER, 2018-2032 (USD MILLION)
TABLE 188. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 189. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 190. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 191. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 192. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 193. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 194. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 195. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 196. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 197. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 198. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
TABLE 199. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, 2018-2032 (USD MILLION)
TABLE 200. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, 2018-2032 (USD MILLION)
TABLE 201. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 202. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
TABLE 203. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 204. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, 2018-2032 (USD MILLION)
TABLE 205. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
TABLE 206. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
TABLE 207. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENETIC DISORDER, 2018-2032 (USD MILLION)
TABLE 208. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 209. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 210. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 211. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 212. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 213. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 214. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 215. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 216. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 217. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 218. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
TABLE 219. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, 2018-2032 (USD MILLION)
TABLE 220. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, 2018-2032 (USD MILLION)
TABLE 221. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 222. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
TABLE 223. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 224. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, 2018-2032 (USD MILLION)
TABLE 225. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
TABLE 226. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
TABLE 227. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENETIC DISORDER, 2018-2032 (USD MILLION)
TABLE 228. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, 2018-2032 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, 2018-2032 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, 2018-2032 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENETIC DISORDER, 2018-2032 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 249. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 250. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 251. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 252. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 253. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 254. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 255. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 256. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 257. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 258. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
TABLE 259. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, 2018-2032 (USD MILLION)
TABLE 260. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, 2018-2032 (USD MILLION)
TABLE 261. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 262. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
TABLE 263. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 264. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, 2018-2032 (USD MILLION)
TABLE 265. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
TABLE 266. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
TABLE 267. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENETIC DISORDER, 2018-2032 (USD MILLION)
TABLE 268. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 269. MIDDLE EAST CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 270. MIDDLE EAST CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 271. MIDDLE EAST CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 272. MIDDLE EAST CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 273. MIDDLE EAST CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 274. MIDDLE EAST CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 275. MIDDLE EAST CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 276. MIDDLE EAST CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 277. MIDDLE EAST CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 278. MIDDLE EAST CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
TABLE 279. MIDDLE EAST CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, 2018-2032 (USD MILLION)
TABLE 280. MIDDLE EAST CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, 2018-2032 (USD MILLION)
TABLE 281. MIDDLE EAST CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
T

Companies Mentioned

The key companies profiled in this Cell & Gene Therapy Clinical Trials market report include:
  • Adaptimmune Therapeutics plc
  • Allogene Therapeutics, Inc.
  • Astellas Gene Therapies, Inc.
  • Beam Therapeutics, Inc.
  • bluebird bio, Inc.
  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • Fate Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Iovance Biotherapeutics, Inc.
  • MeiraGTx Holdings plc
  • Novartis AG
  • Orchard Therapeutics Ltd
  • Passage Bio, Inc.
  • Rocket Pharmaceuticals, Inc.
  • Sangamo Therapeutics, Inc.
  • Spark Therapeutics, Inc.
  • uniQure N.V.
  • Vir Biotechnology, Inc.

Table Information

Report AttributeDetails
No. of Pages191
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 13.94 Billion
Forecasted Market Value ( USD ) by 2032 $ 33.38 Billion
Compound Annual Growth Rate15.6%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Cancer Gene Therapy Market - Global Forecast 2026-2032 - Product Image

Cancer Gene Therapy Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Cell & Gene Therapy Services Market - Global Forecast 2026-2032 - Product Image

Cell & Gene Therapy Services Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Gene Therapy Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Therapeutic Area, Type of Vector, Type of Therapy, Type of Gene Delivery Method, Route of Administration, Geographical Regions, Leading Players and Sales Forecast - Product Image

Gene Therapy Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Therapeutic Area, Type of Vector, Type of Therapy, Type of Gene Delivery Method, Route of Administration, Geographical Regions, Leading Players and Sales Forecast

  • Report
  • 972 Pages
  • Global
From
Viral Vector-Based Gene Therapy Global Market Report 2025 - Product Image

Viral Vector-Based Gene Therapy Global Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Gene Therapy Market Size, Share, Trends and Forecast by Gene Type, Vector Type, Delivery Method, Application, and Region, 2025-2033 - Product Image

Gene Therapy Market Size, Share, Trends and Forecast by Gene Type, Vector Type, Delivery Method, Application, and Region, 2025-2033

  • Report
  • 140 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.